Pfizer says pill to treat COVID-19 could be authorized by end of year or early 2022: 'It is a game changer'
Pfizer has announced that new data confirm its antiviral pill is effective at reducing the risk of hospitalization or death from COVID-19.
The company said Tuesday final trial results confirmed the antiviral pill reduced the risk of hospitalization or death for high-risk COVID-19 patients by 89 percent when given within three days of symptoms developing. This confirmed earlier data from a clinical trial. Pfizer executive Annaliesa Anderson previously told The New York Times that those results were "really beyond our wildest dreams."
Additionally, the company said Tuesday that the pill worked against the new Omicron variant of COVID-19 in lab studies, according to The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"This underscores the treatment candidate's potential to save the lives of patients around the world," Pfizer CEO Albert Bourla said.
Pfizer said this new data has been shared with the FDA as part of its Emergency Use Authorization submission, and Bourla told ABC News that the pill could be authorized in the United States by the end of the year or early 2022. "It is a game changer," Bourla also told ABC. "But at the same time, I want to emphasize that no one should use the existence of the pill as an excuse to avoid vaccination."
An FDA advisory panel previously recommended emergency authorization be granted to a COVID-19 pill from Merck. According to CNN, the FDA hasn't yet set a date for when its advisory committee will consider Pfizer's treatment.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Create an account with the same email registered to your subscription to unlock access.
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
'Biden is smart to keep the border-security pressure on'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
Bird flu worries mount as virus found in milk, cows
Speed Read The FDA found traces of the virus in pasteurized grocery store milk
By Peter Weber, The Week US Published
-
Palazzo Durazzo Suites in Genoa: a palatial gem in northern Italy
The Week Recommends Live your Italian dream in this astonishing and recently restored palace in the heart of the city
By Nick Hendry Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published